U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn ’s Leronlimab

VANCOUVER, Washington, March 19, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the“Company " ), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials